Drug updated on 1/24/2024
|Tablet (oral; emtricitabine/tenofovir alafenamide; 200 mg/25 mg
|Nucleoside reverse transcriptase inhibitors (NRTIs)
| Ongoing and
- Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.
- Indicated in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg.
- Indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex. Individuals must have a negative HIV-1 test immediately prior to initiating DESCOVY for HIV-1 PrEP.
Product Monograph / Prescribing Information
|Descovy (emtricitabine and tenofovir alafenamide) Prescribing Information.
|Gilead Sciences, Inc., Foster City, CA
Randomized Controlled Trials